[go: up one dir, main page]

BRPI0607803A2 - forma de dosagem oral compreendendo rosiglitazona - Google Patents

forma de dosagem oral compreendendo rosiglitazona

Info

Publication number
BRPI0607803A2
BRPI0607803A2 BRPI0607803-6A BRPI0607803A BRPI0607803A2 BR PI0607803 A2 BRPI0607803 A2 BR PI0607803A2 BR PI0607803 A BRPI0607803 A BR PI0607803A BR PI0607803 A2 BRPI0607803 A2 BR PI0607803A2
Authority
BR
Brazil
Prior art keywords
dosage form
composition
oral dosage
rosiglitazone
pharmaceutically acceptable
Prior art date
Application number
BRPI0607803-6A
Other languages
English (en)
Inventor
Joanne Heafield
Vincenzo Re
Original Assignee
Sb Pharmco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sb Pharmco Inc filed Critical Sb Pharmco Inc
Publication of BRPI0607803A2 publication Critical patent/BRPI0607803A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

FORMA DE DOSAGEM ORAL COMPREENDENDO ROSIGLITAZONA. Uma forma de dosagem oral, tal como um comprimido em bicamada compreendendo uma primeira camada de uma primeira composição e uma segunda camada de uma segunda composição, cada composição compreendendo 5-[4-[2-(N-metil-N-(2 piridil)amino)etóxi]benzil]tiazolidina-2,4-diona ou um sal ou solvato farmaceuticamente aceitável deste, ('a droga') e um veículo farmaceuticamente aceitável para este, em que a primeira e a segunda composição são organizadas para liberar droga em taxas de liberação diferentes na administração; um processo para preparar tal forma de dosagem e o uso de tal forma de dosagem na medicina.
BRPI0607803-6A 2005-02-07 2006-02-03 forma de dosagem oral compreendendo rosiglitazona BRPI0607803A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0502475.7A GB0502475D0 (en) 2005-02-07 2005-02-07 Novel compositions
PCT/EP2006/000997 WO2006087116A1 (en) 2005-02-07 2006-02-03 Oral dosage form comprising rosiglitazone

Publications (1)

Publication Number Publication Date
BRPI0607803A2 true BRPI0607803A2 (pt) 2009-06-13

Family

ID=34355898

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0607803-6A BRPI0607803A2 (pt) 2005-02-07 2006-02-03 forma de dosagem oral compreendendo rosiglitazona

Country Status (16)

Country Link
US (1) US20080166408A1 (pt)
EP (1) EP1855671A1 (pt)
JP (1) JP2008543723A (pt)
KR (1) KR20070110016A (pt)
CN (1) CN101155586A (pt)
AU (1) AU2006215854A1 (pt)
BR (1) BRPI0607803A2 (pt)
CA (1) CA2595411A1 (pt)
EA (1) EA200701681A1 (pt)
GB (1) GB0502475D0 (pt)
IL (1) IL184790A0 (pt)
MA (1) MA29281B1 (pt)
MX (1) MX2007009492A (pt)
NO (1) NO20074407L (pt)
TW (1) TW200700063A (pt)
WO (1) WO2006087116A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0203296D0 (en) * 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
US8637512B2 (en) * 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
EP1967182A1 (en) * 2007-03-07 2008-09-10 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising a salt of rosigliatazone
US20100323016A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
US20100323015A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
MX2011000636A (es) * 2008-07-18 2011-08-03 Valeant Pharmaceuticals Int Formulacion de liberacion modificada y metodos de uso.
CA2848798C (en) * 2012-02-22 2014-12-23 Duchesnay Inc. Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
US9452181B2 (en) 2013-07-22 2016-09-27 Duchesnay Inc. Composition for the management of nausea and vomiting
BR112016001474A2 (pt) 2013-07-22 2020-04-14 Duchesnay Inc Composição para o controle de náusea e vômito
US9526703B2 (en) 2014-08-29 2016-12-27 Duchesnay Inc. Plurimodal release formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
LT3684344T (lt) * 2017-10-25 2025-09-10 Chiesi Farmaceutici S.P.A. Uždelsto atpalaidavimo deferiprono tabletės ir jų panaudojimo būdai

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5407687A (en) * 1994-02-22 1995-04-18 Glaxo Inc. Ranitidine solid dosage form
DE69939485D1 (de) * 1998-11-12 2008-10-16 Smithkline Beecham Plc Arzneimittel zur gesteuerten freisetzung eines insulin sensibilisators und metformin
TW200517127A (en) * 2003-08-07 2005-06-01 Sb Pharmco Inc Novel composition
US20050163837A1 (en) * 2003-12-31 2005-07-28 Garth Boehm Rosiglitazone formulations

Also Published As

Publication number Publication date
EP1855671A1 (en) 2007-11-21
KR20070110016A (ko) 2007-11-15
US20080166408A1 (en) 2008-07-10
GB0502475D0 (en) 2005-03-16
AU2006215854A1 (en) 2006-08-24
TW200700063A (en) 2007-01-01
IL184790A0 (en) 2007-12-03
MA29281B1 (fr) 2008-02-01
MX2007009492A (es) 2007-09-19
EA200701681A1 (ru) 2007-12-28
JP2008543723A (ja) 2008-12-04
NO20074407L (no) 2007-08-29
WO2006087116A1 (en) 2006-08-24
CN101155586A (zh) 2008-04-02
CA2595411A1 (en) 2006-08-24

Similar Documents

Publication Publication Date Title
AP1545A (en) Hydrochloride salts of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione.
HRP20020416B1 (hr) Novi pripravak i upotreba
BRPI0616077B8 (pt) composição farmacêutica formulada em uma dose única, kit, artigo de manufatura, uso da composição farmacêutica e uso de um ou mais compostos antidiabéticos
WO2007126362A8 (en) Compounds that are agonists of muscarinic receptors and that may be effective in treating pain, alzheimer's disease and/or schizophrenia
NO20074514L (no) Oral doseringsform omfattende rosiglitazon
BRPI0607803A2 (pt) forma de dosagem oral compreendendo rosiglitazona
MX2010002584A (es) Derivados de piperidina como agonistas de receptores muscarinicos.
NO20085271L (no) Muscarin reseptoragonister som er effektive i behandling av smerte, Alzheimers sykdom og schizofreni
EP1781629A4 (en) BENZAMIDINE DERIVATIVES, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
AR045330A1 (es) Forma de dosificacion oral, procedimiento para su preparacion y uso del compuesto 5-(4-(2-(n-metil-n- (2-piridil)amino)etoxi )bencil) tiazolidin-2,4-diona o una sal o solvato farmaceuticamente aceptable del mismo para prepararla
AR059225A1 (es) Sal de citrato, proceso de preparacion y su actividad en terapia
BRPI0607804A2 (pt) braçadeira de lámina despeladora com ranhuras de saìda de gordura
AP1715A (en) The hydrochloride salt of 5-[ 4 -[2 -(n-methyl-n- (2-pyridyl) amino) ethoxy]benzyl]thiazolidine -2,4-dione
PT1446404E (pt) Edisilatos de rosiglitazona e sua utilizacao como antidiabeticos
ECSP034469A (es) Compuesto farmaceutico novedoso
BR0112982A (pt) Sal tartarato de derivado de tiazolidinadiona
BR0111536A (pt) Sal de tiazolidinediona para tratamento de diabetes mellitus
GB0021784D0 (en) Novel pharmaceutical
BR0112984A (pt) Sais tartarato de derivado de tiazolidinodiona
CY1107421T1 (el) Τρυγικα αλατα παραγωγου θειαζολιδινοδιονης
CY1107767T1 (el) Παραγωγο θειαζολιδινοδιονης και χρηση αυτου σαν αντιδιαβητικο
ECSP034528A (es) Sales de sodio de 5-(4-(n-methyl-n-(2-piridil)amino)etoxi)bencil)tiazolidino-2,4-diona
AR118314A1 (es) Composición farmacéutica
ECSP003434A (es) Nuevos compuestos
TH84984B (th) รูปแบบของการให้ยาทางปากซึ่งประกอบด้วย5-[4-[2-(n-เมธิล-n-(2-ไพริดิล)อะมิโน)เอธอกซี]เบนซิล]ไธอะโซลิดีน-2,4-ไดโอน

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: SMITHKLINE BEECHAM (CORK) LIMITED (IE)

Free format text: TRANSFERIDO DE: SB PHARMCO PUERTO RICO INC.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2161 DE 05/06/2012.